Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic CD4+ CD25+ regulatory T cells (gp120-activated)
- Development stage
- Unknown
- Lead developer
- ActiTrexx
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
allogeneic CD4+ CD25+ regulatory T cells (gp120-activated), also known as ATreg, is an adoptive cell therapy developed by ActiTrexx GmbH. The product consists of donor-derived (allogeneic) regulatory T cells (Tregs) that are isolated and subsequently activated ex vivo using the HIV-1 envelope glycoprotein gp120. This activation process, mediated by gp120 binding to the CD4 receptor on Tregs, induces a stable and potent suppressive phenotype. The therapy is primarily being investigated for the prevention and treatment of acute graft-versus-host disease (aGvHD) in adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for various hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome. By administering these pre-activated Tregs early after transplantation, the therapy aims to suppress the donor-derived effector T cell response against host tissues while preserving the beneficial graft-versus-leukemia effect.
- Other names
- GP120-activated regulatory T cellsGP-120-activated regulatory T cellsGP 120-activated regulatory T cellsallogeneic CD4+ CD25+ regulatory T cells
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)IL-2 (Interleukin 2)CD4 (T lymphocyte surface antigen)Neuraminidase
Beyond the preview
Go deeper on allogeneic CD4+ CD25+ regulatory T cells (gp120-activated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic CD4+ CD25+ regulatory T cells (gp120-activated).